Denali Therapeutics Inc. — Director's Dealing 2021

Jun 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-06-04

Reporting Person: Schuth Alexander O. (COO and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-04	Common Stock	S	5660	$64.346	Disposed	505922	Indirect
2021-06-04	Common Stock	S	4340	$64.816	Disposed	501582	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	91454	Direct

Footnotes

F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.

F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $63.70 to $64.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.70 to $64.91 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F5: Includes 80,358 restricted stock units.

F6: Includes 410 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan purchased on June 1, 2021.